ArticleClinical cardiology2026
Tumor Necrosis Factor Superfamily 14: A Potential Predictor of Atrial Fibrillation Recurrence After Catheter Ablation.
Article in Clinical cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
backgroundTumor necrosis factor superfamily 14 (TNFSF14) has been implicated in the pathogenesis of cardiovascular disease, including atrial fibrillation (AF). However, its role in predicting AF recurrence after catheter ablation (CA) remains unexplored.
objectiveThis study aimed to evaluate the predictive value of TNFSF14 for AF recurrence post-ablation.
methodsA total of 263 AF patients undergoing CA were enrolled and stratified into two groups based on AF recurrence during a mean follow-up of 363 ± 144 days. Plasma TNFSF14 levels were measured by enzyme-linked immunosorbent assay (ELISA). Cox proportional hazards models were employed to examine the association between TNFSF14 levels and AF recurrence, while Receiver Operating Characteristic (ROC) analysis was used to assess predictive performance.
resultsAF recurrence occurred in 81 patients (30.8%). Patients with recurrence exhibited significantly higher baseline TNFSF14 levels (1.21 ± 0.24 vs. 1.02 ± 0.29 ng/mL, p < 0.001). Elevated TNFSF14 levels were independently associated with AF recurrence (Adjusted hazard ratio (aHR): 3.65, 95% CI: 2.19-6.09, p < 0.001). ROC analysis demonstrated moderate predictive power for TNFSF14 (AUC: 0.70). Incorporating TNFSF14 levels into the ATLAS score and BNP significantly enhanced the predictive performance for recurrence, as evidenced by improved time-dependent AUC, decision curve analysis, net reclassification improvement (NRI: 0.36, p < 0.001) and integrated discrimination improvement (IDI: 0.08, p = 0.012).
conclusionsTNFSF14 is a promising biomarker for predicting AF recurrence after CA. It holds potential for inclusion in future personalized risk models for AF recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.